Rights and permissions
About this article
Cite this article
Pioglitazone, rosiglitazone face up to MI, HF risk analyses. Inpharma Wkly. 1605, 19 (2007). https://doi.org/10.2165/00128413-200716050-00053
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200716050-00053